【摘要】 [目的]研究亚甲基四氢叶酸还原酶基因(MTHFR)C677T多态对接受氟尿嘧啶(5-Fu)为基础辅助化疗胃癌患者预后的影响。[方法]确诊的胃癌患者110例,采用5-Fu为基础的方案进行辅助化疗。采用聚合酶链反应—连接酶检测反应技术检测MTHFRC677T基因多态。[结果]110例胃癌患者中,MTHFR677T/T、C/T和C/C基因型频率分别为19.1%(21/110)、47.3%(52/110)和33.6%(37/110)。110例患者复发率和死亡率分别为54.5%(60/110)和42.7%(47/110)。携带C/C基因型患者无复发生存率和总生存率均显著低于携带T/T或C/T基因型患者(P<0.05)。Cox多因素分析显示,MTHFRC/C基因型是影响患者复发和生存的独立危险因素(P<0.05)。[结论]MTHFRC677T基因多态性是接受5-Fu为基础辅助化疗胃癌患者的独立预后因素。更多还原

【Abstract】 [Purpose] To investigate the impact of methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism on prognosis in gastric cancer patients treated with 5-Fu-based adjuvant chemotherapy. [Methods] One hurdred and ten cases with gastric cancer were treated with 5-Fu-based adjuvant chemotherapy. MTHFR C677T polymorphism in those patients was determined by PCR-LDR (ligation detection reaction) methods. [Results] Of the 110 patients, the frequencies of MTHFR 677 T/T, C/T and C/C genotype were 19.1%(21/110), 47.3%(52/110) and 33.6%(37/110), respectively. The recurrence rate and mortality in 110 cases were 54.5%(60/110) and 42.7%(47/110), respectively. The recurrence-free and overall survival rates in patients with C/C genotype were significantly lower than those in patients with T/T or C/T genotype (P<0.05). Cox multivariate analysis showed that MTHFR C677C genotype was independent risk factor influencing recurrence and survival (P<0.05). [Conclusion] Polymorphism of MTHFR C677T may be a potential prognostic factor in gastric cancer patients treated with 5-Fu-based adjuvant chemotherapy.更多还原